What is Saama?
Founded in 1997 and headquartered in Campbell, California, Saama Technologies operates at the intersection of artificial intelligence and clinical research. The company provides a sophisticated AI-driven clinical data analytics platform designed to integrate, curate, and animate diverse data streams—ranging from structured clinical trial data to unstructured real-world evidence. By delivering actionable insights across all therapeutic areas, Saama enables biopharmaceutical organizations to streamline complex development cycles, reduce time-to-market for life-saving therapies, and enhance the overall efficacy of clinical operations. Its market position is defined by its ability to bridge the gap between raw data silos and high-level strategic decision-making in the healthcare sector.
How much funding has Saama raised?
Saama has raised a total of $507M across 4 funding rounds:
Series A
$35M
Private Equity
$40M
Debt
$2M
Other Financing Round
$430M
Series A (2015): $35M with participation from Carrick Capital Partners
Private Equity (2019): $40M led by Perceptive Advisors
Debt (2020): $2M supported by PPP
Other Financing Round (2021): $430M featuring Amgen Business Development, Merck Global Health Innovation Fund, and Northpond Ventures
Key Investors in Saama
Amgen Business Development
Amgen Oncology is a leader in transforming cancer treatment through innovative therapies and a commitment to patient care, focusing on high-quality biosimilar medicines.
Merck Global Health Innovation Fund
A growth investor that partners with innovative digital health and data science companies to facilitate and optimize biopharmaceutical operations.
Perceptive Advisors
An investment firm managing significant assets, dedicated to funding innovative healthcare and life sciences technologies.
What's next for Saama?
With the infusion of capital from its most recent financing rounds, Saama is well-positioned to scale its enterprise-level operations and deepen its technological moat. The company is expected to prioritize the expansion of its AI capabilities, focusing on predictive modeling and real-time data synthesis to further optimize biopharmaceutical workflows. As the industry shifts toward decentralized and data-heavy clinical trials, Saama's strategic roadmap likely involves enhancing its interoperability with global health systems and expanding its footprint in emerging therapeutic markets. This growth phase will be critical in maintaining its competitive advantage as a leader in the digital transformation of clinical development.
See full Saama company page
